Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inclusive Search for Anomalous Single-Photon Production in MicroBooNE.

Physical review letters·2026
Same author

First Search for Dark Sector e^{+}e^{-} Explanations of the MiniBooNE Anomaly at MicroBooNE.

Physical review letters·2026
Same author

A two-mode thermomechanically squeezed phonon laser.

Nature communications·2026
Same author

First Measurement of Charged-Current Muon-Neutrino-Induced K^{+} Production on Argon Using the MicroBooNE Detector.

Physical review letters·2026
Same author

Measurement of the Positive Muon Anomalous Magnetic Moment to 127 ppb.

Physical review letters·2025
Same author

Simultaneous Maxillofacial, Abdominal, and Bone Marrow Involvement in a Pediatric Patient With Epstein-Barr Virus-Associated Burkitt Lymphoma: A Case From India.

Cureus·2025
Same journal

Assessment of exclusive breastfeeding practices in a tribal district of Maharashtra: A cross-sectional study.

Journal of postgraduate medicine·2026
Same journal

Leveraging immersive technology with virtual emulation for training of nonmedico combatants: A randomized controlled trial.

Journal of postgraduate medicine·2026
Same journal

From clinic to microscope: A study of clinicopathological concordance in 5000 skin biopsies from a tertiary care center.

Journal of postgraduate medicine·2026
Same journal

Early anticoagulation with warfarin for pulmonary embolism complicating active gastric ulcer: A case against guideline-mandated delay.

Journal of postgraduate medicine·2026
Same journal

Paradoxical Hemophagocytic Lymphohistiocytosis to Stevens-Johnson Syndrome - Toxic Epidermal Necrolysis- A rare immune phenomenon.

Journal of postgraduate medicine·2026
Same journal

Anesthetic management of neonate with hypoplastic left heart syndrome posted for exploratory laparotomy.

Journal of postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Posaconazole.

M Bhattacharya1, K Rajeshwari, B Dhingra

  • 1Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, India.

Journal of Postgraduate Medicine
|July 13, 2010
PubMed
Summary
This summary is machine-generated.

Posaconazole, a novel triazole antifungal, shows high efficacy in preventing and treating invasive fungal infections in immunocompromised patients. Its favorable safety profile makes it a valuable therapeutic option.

More Related Videos

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
09:06

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Jun 11, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
09:06

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Invasive fungal infections (IFIs) pose a significant threat, particularly in immunocompromised populations.
  • The Human Immunodeficiency Virus (HIV) pandemic and advancements in cancer therapy and transplantation have increased the incidence of IFIs.
  • There is a need for effective and safe antifungal agents to manage these infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of posaconazole as a novel second-generation triazole antifungal agent.
  • To highlight the role of posaconazole in prophylaxis and salvage therapy for various invasive fungal infections.

Main Methods:

  • Review of clinical data and studies on posaconazole's use in immunocompromised patients.
  • Analysis of posaconazole's effectiveness against specific fungal pathogens like Aspergillus and Candida species.
  • Assessment of posaconazole's adverse effect profile.

Main Results:

  • Posaconazole demonstrates high efficacy in the prophylaxis of invasive fungal infections.
  • It is effective as both a first-line agent and for salvage therapy in conditions such as aspergillosis and candidiasis.
  • Posaconazole exhibits a favorable adverse effect profile compared to other antifungal agents.

Conclusions:

  • Posaconazole is a valuable second-generation triazole antifungal agent.
  • Its efficacy, broad spectrum of activity, and good safety profile make it an important therapeutic option for invasive fungal infections.
  • Posaconazole represents a significant addition to the antifungal armamentarium, especially given the rising incidence of IFIs.